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Although RAF kinases are critical for controlling
cell growth, their mechanism of activation is incom-
pletely understood. Recently, dimerization was
shown to be important for activation. Here we show
that the dimer is functionally asymmetric with one
kinase functioning as an activator to stimulate activ-
ity of the partner, receiver kinase. The activator
kinase did not require kinase activity but did require
N-terminal phosphorylation that functioned allo-
sterically to induce cis-autophosphorylation of the
receiver kinase. Based onmodeling of the hydropho-
bic spine assembly, we also engineered a constitu-
tively active mutant that was independent of Ras,
dimerization, and activation-loop phosphorylation.
As N-terminal phosphorylation of BRAF is constitu-
tive, BRAF initially functions to activate CRAF. N-ter-
minal phosphorylation of CRAF was dependent on
MEK, suggesting a feedback mechanism and
explaining a key difference between BRAF and
CRAF. Our work illuminates distinct steps in RAF
activation that function to assemble the active
conformation of the RAF kinase.INTRODUCTION
The RAS-RAF-MEK-ERK signaling pathway is key for a variety of
cellular functions including controlling cell proliferation and sur-
vival (Baccarini, 2005; Wellbrock et al., 2004). Dysregulation of
this pathway is also important in cancer with most tumors exhib-
iting mutations in RAS and/or RAF (Brose et al., 2002). Although
heavily studied over the last 20 years, the exact mechanism of
RAF activation remains complex and largely unknown. Activa-
tion of RAF involves both phosphorylation and dephosphoryla-
tion, as well as binding to accessory proteins and lipids.1036 Cell 154, 1036–1046, August 29, 2013 ª2013 Elsevier Inc.There are three isoforms of RAF: A-RAF, B-RAF, and C-RAF.
Each appears to have a distinct mechanism of activation (Baljuls
et al., 2007; Galabova-Kovacs et al., 2006; Wimmer and Baccar-
ini, 2010). BRAF is considered to be more active and have a
simpler mechanism of activation in comparison to CRAF and
ARAF (Chong et al., 2001; Rebocho and Marais, 2013; Zhang
and Guan, 2000). This difference can potentially explain why
BRAF mutations are so common in cancer, in contrast to
CRAF and ARAF, where mutations are rarely found (Davies
et al., 2002).
Recently, new insights into the mechanism of RAF activation
were unexpectedly revealed by the effect of RAF inhibitors (Hat-
zivassiliou et al., 2010; Heidorn et al., 2010; Poulikakos et al.,
2010). These drugs are effective inhibitors of RAF kinase activity,
but when used at subsaturating doses, they paradoxically acti-
vate the RAF pathway. Current models suggest that when RAF
is bound to an inhibitor, it dimerizes with other RAF molecules,
stimulating kinase activity in the partner molecule that is not
bound to the inhibitor. A dimerization-dependent mechanism
of RAF activation (Farrar et al., 1996; Weber et al., 2001) is sup-
ported bywork showing that kinase-dead forms of BRAF, but not
CRAF, are oncogenic and can allosterically activate BRAF and
CRAF (Garnett et al., 2005; Wan et al., 2004). Additional experi-
ments suggest that BRAF can activate CRAF, but CRAF cannot
activate BRAF (Garnett et al., 2005; Poulikakos et al., 2010).
Dimerization is, therefore, not sufficient by itself to explain the
mechanism of RAF activation.
The activation of RAF requires phosphorylation at two different
sites. One of these sites is the activation loop (AL) of the kinase
where phosphorylation of two residues is required (Chong
et al., 2001; Zhang and Guan, 2001). The other site is in a region
close to the N terminus of the kinase domain, a segment some-
times referred to as the N-terminal acidic (NtA) motif (Diaz et al.,
1997; Marais et al., 1995; Mason et al., 1999). In BRAF, the NtA
motif contains residues SSDD (S = serine, D = aspartic acid).
Because one or more of the serines are constitutively phosphor-
ylated, at least three of the four residues are acidic in the resting
kinase (Mason et al., 1999). In CRAF and ARAF, the sequences
are SSYY and SGYY, respectively (Y = tyrosine, G = glycine).
Phosphorylation of these residues is not present in the resting
kinase and is thought to occur when CRAF and ARAF are
recruited to the plasma membrane by activated RAS (Morrison
and Cutler, 1997). The current model suggests that at the plasma
membrane, the tyrosines are phosphorylated by Src family tyro-
sine kinases, whereas the serines are phosphorylated by p21-
activated kinase (PAK) or protein kinase C (PKC) family kinases
(Fabian et al., 1993; King et al., 1998; Kolch et al., 1993). The
role of PAKs in RAF phosphorylation is, however, controversial
(Chiloeches et al., 2001).
Previously, we reported that substitution of a conserved
alanine with phenylalanine in the kinase domains of CRAF
(A373F), BRAF (A471F), and KSR1 (A587F) blocks ATP binding
but allows for constitutive dimerization (Hu et al., 2011). We
used the ability of these inactivemutants to generate RAF dimers
where one component was active (the receiver) and the second
(the activator) was not. Using this approach, we could determine
the requirements for allosteric activation of RAF. We found that
NtA-motif phosphorylation, which is constitutive in BRAF, was
necessary on the activator but not the receiver. This explains
why kinase-inactive BRAF can transactivate CRAF but not vice
versa. When the NtA is phosphorylated on CRAF or KSR1, how-
ever, both can function as allosteric activators of BRAF or CRAF.
Importantly, allosteric activation induced cis-autophosphoryla-
tion of the AL of the receiver molecule. NtA phosphorylation of
CRAF involved mitogen-activated protein kinase kinase (MEK),
indicating a positive feedback mechanism that converted
CRAF into an activator. These data help to explain the distinct
roles of BRAF, CRAF, and KSR1 in mitogen-activated protein
kinase (MAPK) activation and also provide a unifying model for
RAF activation.
RESULTS
RAF Transactivation Requires Phosphorylation of the
NtA Motif
Kinase-dead forms of BRAF occur in human cancers and are
oncogenic (Garnett et al., 2005; Wan et al., 2004). By dimeriz-
ing with wild-type CRAF, kinase-dead forms of BRAF can acti-
vate MEK and subsequently extracellular signal-regulated ki-
nase (ERK). We had previously found that, in contrast to
BRAF, expression of kinase-dead, dimerizing forms of CRAF
and KSR1 have no effect on ERK activation (Hu et al., 2011).
To determine what feature of BRAF accounts for this differ-
ence, we truncated ATP-binding deficient BRAF (A481F) by
removing the N-terminal 434 or 454 residues and tested
whether these truncated proteins could still induce ERK activa-
tion (Figure 1A). The mutant lacking the first 434 residues could
activate ERK, whereas the mutant lacking the first 454 residues
could not. This suggested that the ability of kinase-dead forms
of BRAF to activate ERK requires residues between 434
and 454.
Residues 446–449 of BRAF (SSDD) form an acidic motif just
N-terminal to the kinase domain. S446 is constitutively phos-
phorylated in BRAF and is important for activation as mutation
of this residue attenuates BRAF kinase activity (Marais et al.,
1997; Mason et al., 1999). To validate whether these residues
are required for kinase-dead BRAF to stimulate ERK activation,we substituted four alanine residues for residues 446–449 (Fig-
ure 1B). Overexpression of this BRAF mutant (BRAF-A481F/
AAAA) did not stimulate ERK activation, suggesting that these
residues are critical for the ability of kinase-dead BRAF to stim-
ulate ERK.
In CRAF, the sequence corresponding to 446–449 of BRAF is
SSYY at position 338–341. In contrast to BRAF, these residues
are not constitutively phosphorylated; rather their phosphoryla-
tion is induced during the process of CRAF activation (Chong
et al., 2001; Mason et al., 1999). Phosphorylation of two of these
residues (S338 and Y441) is required for CRAF activation as
mutation of either residue to alanine abrogates kinase activity
(Mason et al., 1999). To determine whether the absence of phos-
phorylation at these positions explains the inability of kinase-
dead CRAF to stimulate ERK activation, we substituted DDEE
(where E = glutamic acid) for residues 338–341 in kinase-dead
CRAF (A373F). Overexpression of the CRAF mutant (A373F/
DDEE) stimulated ERK phosphorylation when expressed in cells
(Figure 1C). Similarly, substitution of the equivalent sequence in
KSR1 (552–555, YLQE) with DDEE allowed a kinase-dead form
of KSR1 (A587F/DDEE) to stimulate ERK activity in cells (Fig-
ure 1D). Because position 555 is already a glutamic acid in
KSR1 and because Y552 is the only residue in the sequence
that could be potentially phosphorylated, we generated amutant
where only Y552 was replaced with aspartic acid. The single
mutation functioned as efficiently as the DDEE mutant in ERK
activation, suggesting that if Y552 of KSR1 could be phosphor-
ylated, it could function to activate ERK (Figure 1D).
Because tyrosine phosphorylation of KSR1 has not been
reported (Cacace et al., 1999) and because several predicted
serine and threonine phosphorylation sites are located close to
Y552 (T549/S550) (Blom et al., 2004), we tested whether acidic
substitutions at these positions could stimulate ERK. Acidic
residue substitution for T549 and S550 in kinase-dead KSR1
stimulated ERK activation in cells (Figure 1D). This suggests
that phosphorylation of serine/threonine or tyrosine residues in
KSR1 could activate RAF. It also suggests that phosphorylation
beyond the four-residue NtA motif could be important in
transactivation.
To confirm that dimerization is required, dimerization-impair-
ing forms of kinase-dead BRAF (R509H), CRAF (DDEE/R401H),
and KSR1 (DDEE/R615H) (Rajakulendran et al., 2009) were
tested. As expected, impairing dimerization of the BRAF (Fig-
ure 1E), CRAF (Figure 1F), and KSR1 (Figure 1G) mutants
strongly attenuated ERK activation. This confirms that kinase-
dead forms of RAF or KSR1 can transactivate wild-type RAF
molecules using a mechanism that requires dimerization and
NtA residues. It also demonstrates that the RAF dimer is not
functionally symmetrical.
The Requirements for Activator versus Receiver Kinase
Are Distinct
We took advantage of the fact that kinase-dead forms of BRAF,
CRAF, and KSR1 could function as transactivators to function-
ally separate the RAF dimer into an ‘‘activator’’ component
(dead) and a ‘‘receiver’’ component (live), as proposed for other
dimeric kinases (Zhang et al., 2006). To simplify the nomencla-
ture, we will refer to kinase-dead BRAF (A481F) or the acidicCell 154, 1036–1046, August 29, 2013 ª2013 Elsevier Inc. 1037
Figure 1. The Ability of Kinase-Dead BRAF
to Activate ERK Requires Phosphorylation
of the NtA
(A) The NtA is required for BRAF transactivation.
Kinase-dead full-length BRAF (A481F) (lane 2) or
truncated forms of BRAF A481F (D434—lane 3,
D454—lane 4) were transiently overexpressed in
293 cells and cell lysates immunoblotted for ERK
activation (pERK) after 24 hr.
(B) Substitution of alanines (AAAA) for residues
446–449 of BRAF A481F impaired ERK activation.
Expression and immunoblotting were as de-
scribed in (A).
(C) Substitution of acidic residues (DDEE) for res-
idues 338–341 of kinase-dead CRAF (A373F)
conferred the ability to transactivate. ERK activa-
tion was measured as described in (A).
(D) Acidic residues substituted in dimerization-
competent, kinase-dead KSR1 (A587F) confer the
ability to transactivate. Overexpression of kinase-
dead KSR1 (A587F) had no effect on ERK activa-
tion, whereas substitution of acidic residues
(DDEE) for residues 552–555 of KSR1, for Y522
(Y522E), or for T549 and S550 (TESD) could confer
the ability to transactivate. In all panels, the mu-
tants were overexpressed and analyzed as in (A).
(E–G) Transactivation by kinase-dead BRAF (E),
CRAF (F), or KSR1 (G) involves dimerization.
Replacement of an arginine residue critical for
efficient dimerization impaired the ability of BRAF
A481F (E) and mutated forms of CRAF (A383F/
DDEE) (F) and KSR1 (A587F/DDEE) (G) to activate
ERK. ERK activation was measured as in (A).mutants of kinase-dead CRAF (A373F/DDEE) and KSR1 (A587F/
DDEE) as ‘‘activators.’’ The enzymatically active form of BRAF or
CRAF will be referred to as a ‘‘receiver.’’
To determine whether the NtA motif was required on both the
activator and the receiver, as is implied by current models, we
tested whether a CRAF receiver mutant that cannot be phos-
phorylated on residues 338–341 (AAFF substituted for SSYY)
could be activated by activator forms of BRAF and CRAF (Fig-
ure 2A). Coexpression of the CRAF/AAFF receiver with activator
forms of BRAF and CRAF stimulated ERK (Figure 2A). Similar
results were obtained when a BRAF receiver with four alanines
substituted for residues 446–449 was tested (Figure 2B). As
expected, impairing dimerization also impaired transactivation
(Figures 2A and 2B). Given that the R to H mutant doesn’t
completely block dimerization, we also generated another
mutant that more severely impaired dimerization, and it showed
even less transactivation (Figure S1 available online). Thus phos-
phorylation of the NtA motif is required only on the activator
kinase and demonstrates that NtA phosphorylation is not
required for CRAF kinase activity.1038 Cell 154, 1036–1046, August 29, 2013 ª2013 Elsevier Inc.In vitro kinase assays confirmed that
the receivers were catalytically activated.
The CRAF-AAFF (Figure 2C) or BRAF-
AAAA (Figure 2D) receiver mutants were
coexpressed with activator forms of
BRAF and CRAF. Immunoprecipitatesprepared with antibodies to the epitope tag attached to the
receiver kinases were tested in vitro for kinase activity against
MEK1. Although the BRAF and CRAF receiver kinases had little
detectable kinase activity by themselves, coexpression with
BRAF and CRAF activators strongly induced their kinase activity
toward MEK1 (Figures 2C and 2D).
The Mechanism of Transactivation Requires a
Conserved Tryptophan
Multiple dimeric structures of BRAF and CRAF have been solved
(Hansen et al., 2008; Hatzivassiliou et al., 2010; King et al., 2006;
Tsai et al., 2008;Wan et al., 2004). These structures do not reveal
a clear localization of the NtA motif in the dimer interface. Some
of the structures of CRAF do show that a conserved tryptophan
(CRAF-342, BRAF-450, KSR1-556) is a component of the dimer
interface (Hatzivassiliou et al., 2010) and is positioned adjacent
to the critical arginine residue required for dimerization (CRAF-
R401, BRAF-R509, KSR-R615) (Figure 3A) (Rajakulendran
et al., 2009). As the conserved tryptophan is the first residue
following the NtA motif (Figure 3B), it may be important in the
Figure 2. Phosphorylation of the Acidic Motif Is Required on the
Activator but Not the Receiver RAF Kinase
(A) A mutated form of truncated, catalytically active CRAF (D1–322) with AAFF
substituted for residues 338–341 was transiently coexpressed with kinase-
dead BRAF (A481F, D1-434—left panel) or with acidic, kinase-dead CRAF
(A373F/DDEE, D1–322—right panel) with and without dimerization mutations
(R509H or R401H) in 293 cells. Cell lysates were immunoblotted with anti-
bodies to pERK1/2, ERK2, MYC (receiver constructs), or FLAG (activator
constructs).
(B) A mutated form of truncated, catalytically active BRAF (D1–434) with AAAA
substituted for residues 446–449 was transiently coexpressed with kinase-
dead BRAF (A481F, D1–434—left panel) or with acidic, kinase-dead CRAF
(A373F/DDEE, D1–322—right panel). Impairing dimerization (BRAF/R509H,
CRAF/R401H) impaired transactivation. See also Figure S1. Cell lysates were
analyzed as described in (A).
(C and D) Activation of receiver CRAF (C) or BRAF (D) kinase activity measured
by in vitro kinase reaction. The CRAF (AAFF,D1–322) or BRAF (AAAA, D1–434)
receiver constructs were coexpressed with empty vector, BRAF, or CRAF
activator constructs. Immunoprecipitates were prepared using an antibody to
the MYC tag present on the receiver. In vitro kinase reactions were performed
with purified MEK as the substrate and measured by immunoblotting with
antibodies to pMEK. Immunoblotting with antibodies to MYC (receiver) or
FLAG (activator) confirmed similar levels of expression.mechanism of transactivation. Sequence alignment showed that
this tryptophan is identical in position to W238 in LCK, W258 in
SRC,W235 in ABL, andW391 in BTK and functionally equivalent
to L680 of the epidermal growth factor receptor (EGFR) (Zhang
et al., 2006) (Figure 3B).Replacing tryptophan with alanine impaired the ability of BRAF
or CRAF to function either as an activator (Figures 3C and 3D) or
as a receiver (Figure 3E). Since the tryptophan is part of the dimer
interface, we also tested the CRAFW342A mutant in a dimeriza-
tion assay. Compared to the CRAF R401H mutant, the CRAF
W342A mutant had a smaller effect on dimerization when
mutated in either the activator or the receiver as measured by
coimmunoprecipitation (Figures 3F and 3G) or by luciferase
complementation (Figure S1). This suggests that the conserved
tryptophan residue is important in positioning the NtA residues
in the dimer interface for transactivation.
Dimerization Induces Phosphorylation of the AL
Since dimerization is not sufficient by itself to activate CRAF or
BRAF, we considered that the NtA motif functions to induce AL
phosphorylation, which is also required for activation (Chong
et al., 2001; Zhang andGuan, 2000). A phosphospecific antibody
to the AL showed that phosphorylation was induced on the
receiver but not the activator kinase (Figure 4A, compare lane
1 versus 3). This was specific as a mutant with the AL phosphor-
ylation sites mutated to alanine (TASA) did not react with the
antibody (Figure 4A, lanes 2 and 4). Since the activator is not
catalytically active, AL phosphorylation likely occurs by cis-
autophosphorylation.
A Mutation that Preassembles the Active Conformation
Circumvents All of the Activation Steps
Cis-autophosphorylation is unusual and implies that the active
conformation was formed prior to autophosphorylation. This
suggested that transactivation functions to assemble the active
conformation of the receiver as a prerequisite for AL phosphory-
lation. Previously, our work defining the hydrophobic core of
active kinases proposed that all active kinases assemble a struc-
ture called the regulatory hydrophobic spine (R-spine) (Taylor
and Kornev, 2011). In the dimeric CRAF and BRAF structures,
the R-spine is only partially assembled with interactions seen be-
tween the top two residues, BRAF: F516 and L505 (Figure 4C,
left panel) or CRAF: F408 and L397 (data not shown). The phenyl-
alanine in the key DFG motif can be displaced rearward in the
DFG ‘‘out’’ position in the inactive kinase (Figure 4C, middle
panel—inactive) or in the DFG ‘‘in’’ position in the active position
in the R-spine (Figure 4C, left panel—active) (Hansen et al., 2008;
Wan et al., 2004). We therefore considered that dimerization and
the NtA residues function by positioning the DFG motif into the
R-spine of the receiver, as required for the active conformation.
To test this hypothesis, we reasoned that if the R-spine was
already assembled, dimerization and AL phosphorylation would
be unnecessary. Modeling suggested that substitution of L397 in
the aC helix with phenylalanine, a larger more hydrophobic res-
idue, might stabilize the R-spine by promoting hydrophobic in-
teractions with F408 above and F487 below (Figure 4C, right
panel).
As predicted, replacement of CRAF L397 and BRAF L505 with
phenylalanine resulted in a strong, constitutively active kinase
consistent with assembly of the R-spine (Figure 4B). Replace-
ment of the two AL phosphorylation sites, T491 and S494, with
alanines (TASA) of CRAF had no effect on its activity, suggesting
that if the R-spine is stably assembled, AL phosphorylation is noCell 154, 1036–1046, August 29, 2013 ª2013 Elsevier Inc. 1039
Figure 3. The Mechanism of Transactiva-
tion Involves a Conserved Tryptophan
(A) Schematic diagram showing the position of the
W342 in the CRAF dimer interface. Note the close
proximity of W342 to R401, the residue critical for
dimerization, and the position of the unphos-
phorylated Y340 and Y341. Blue and green are
used to distinguish the two components of the
dimer. Residue numbers between each kinase are
also distinguished with a ‘‘prime.’’
(B) Alignment of the N-terminal motifs of human
BRAF, CRAF, KSR1, KSR2, LCK, SRC, ABL, BTK,
EGFR, and PKA shows the conservation of the
tryptophan in all of the kinases except for PKA and
EGFR. In EGFR, L680 is the functional equivalent
of the tryptophan (Zhang et al., 2006).
(C and D) Mutation of the tryptophan on the acti-
vator kinase impairs ERK activation. Activator
forms of BRAF (C) or CRAF (D) with andwithout the
tryptophan mutation (BRAF W450A or CRAF
W342A) were transiently coexpressed in 293 cells
with CRAF receiver (AAFF,D1–322) in cells and cell
lysates immunoblotted with antibodies to pERK,
ERK2, HA (activator), and Myc (receiver).
(E) Mutation of tryptophan on the receiver impairs
ERK activation. CRAF activator construct (CRAF
A373F/DDEE, D1–322) was transiently coex-
pressed in 293 cells with either empty vector,
CRAF receiver (AAFF, D1–322), or CRAF receiver
with the tryptophan mutated (AAFF/W342A, D1–
322). Cell lysates were prepared and immuno-
blotted with antibodies to pERK, ERK2, HA (acti-
vator), and Myc (receiver).
(F) Mutation of the tryptophan on the activator only
modestly impairs dimerization. A CRAF receiver
construct (AAFF, D1–322) was coexpressed with
vector alone, a CRAF activator (A373F/DDEE), the
CRAF activator with the tryptophan mutation
(A373F/DDEE/W342A), or the CRAF activator with
the R401H dimerization mutation. Immunoprecip-
itates were made with antibodies to the activator
(HA) and immunoblotted with antibodies to the
receiver (Myc). See also Figure S1.
(G) Mutation of the tryptophan on the receiver only
moderately impairs dimerization. The CRAF
receiver construct (CRAF AAFF, D1–322) with the
tryptophan mutation (W342A) or the dimerization
mutation (R401H) was transiently expressed alone
or coexpressed with a CRAF activator construct
(A373F/DDEE, D1–322). Immunoprecipitates were
made with antibodies to the activator (HA) and im-
munoblotted with antibodies to the receiver (Myc).longer required (Figure 4B). Impairing the ability of CRAF L397F
or BRAF L505F to dimerize had only a small effect on either con-
struct’s ability to activate ERK. This suggested that the R-spine
mutation stabilizes the active conformation but does not do so
completely. These data suggest a temporal series of events
where dimerization and NtA motif phosphorylation of the acti-
vator induce formation of the R-spine on the receiver. Assembly
of the R-spine then allows for AL phosphorylation that may func-
tion to further stabilize the active conformation.
Lastly, we tested whether the CRAF L397F mutant displayed
kinase activity and AL phosphorylation when expressed in bac-
teria. The CRAF L397F mutant was insoluble in bacteria, but the1040 Cell 154, 1036–1046, August 29, 2013 ª2013 Elsevier Inc.CRAF DDEE/L397F was soluble, active, and displayed AL phos-
phorylation (Figure 4D and data not shown). When the ATP-bind-
ing-deficient form of CRAF (A373F) was coexpressed with CRAF
L397F in bacteria, AL phosphorylation was detected only on
CRAF L397F and not CRAF A373F (Figure 4E). Altogether, this
supports a model where AL phosphorylation occurs by cis-
autophosphorylation.
NtA Motif Phosphorylation of CRAF Is MEK Dependent
Because S338 phosphorylation was not required on the CRAF
receiver, we considered that S338 phosphorylation might func-
tion as a feedback mechanism that occurs after RAF activation
Figure 4. Constitutive Assembly of the R-
Spine Results in an Active Kinase that
Does Not Require Dimerization or AL Phos-
phorylation
(A) Phosphorylation of the AL is induced on the
receiver but not the activator. An HA-tagged CRAF
activator (A373F/DDEE, D1–322) was coex-
pressed with a FLAG-tagged CRAF receiver
(AAFF, D1–322). Immunoprecipitates were made
to the receiver (anti-FLAG, lanes 1 and 2) or to the
activator (anti-HA, lanes 3 and 4) and immuno-
blotted with a phosphospecific antibody to BRAF
pT599, which also specifically reacts with pT491 of
CRAF. Mutation of the AL phosphorylation sites
(T491A, S494A) verified the specificity of the anti-
body (lanes 2 and 4).
(B) CRAF L397F and BRAF L505F mutants are
constitutively active and do not require AL phos-
phorylation or dimerization. CRAF L397F and
BRAF L505F mutants were transiently overex-
pressed in 293 cells and cell extracts immuno-
blotted with antibodies to pERK, ERK2, or HA
(CRAF or BRAF). CRAF mutant with mutations in
the AL phosphorylation sites (T491A, S494A) had
no effect on ERK activation. Similarly, dimerization
mutants of the CRAF L397F mutant (R401H or RH)
and BRAF L505F (R509H or RH) had only minor
effects on ERK activation.
(C) Schematic diagram showing the positions of
the R-spine residues in BRAF. In the left panel, the
conformation of the R-spine in the active confor-
mation is shown (Protein Data Bank [PDB] ID code
4E26). In the middle panel, the position of the
residues of the R-spine in the inactive, dimeric
structure of BRAF is shown (PDB ID code 1UWH).
Note the rearward displacement of F595. In the
right panel, a model predicting the structure of the
L397F mutant is shown. This was modeled using
TINKER (http://dasher.wustl.edu/tinker/).
(D) Kinase activity of bacterially expressed CRAF
L397F/DDEEmutant. GST fusion protein of L397F/
DDEE or wild-type CRAF/DDEE kinase domain
was purified with GST and tested in vitro for kinase
activity in vitro toward purified MEK.
(E) Coexpression of His-tagged CRAF L397F/
DDEE construct with GST-CRAF/A373F mutant in
bacteria. Bacteria were lysed, and proteins puri-
fied with glutathione or Ni2+ beads and immuno-
blotted with BRAF pT599 antibody.rather than, as currently believed, before activation. Pretreat-
ment of cells with two different MEK inhibitors blocked a signif-
icant fraction of S338 phosphorylation induced by EGF (Figures
5A, 5B, and S2) or by BRAF inhibitor (Figure S2). This was
specific as PAK and CAMKII inhibitors had no effect. This dem-
onstrates that MEK plays a major role in the induction of S338
phosphorylation, but the residual phosphorylation suggests
that other mechanisms of S338 phosphorylation also exist. Co-
expression of a constitutively active form of MEK with CRAF
induced strong S338 phosphorylation that was completely
blocked by MEK inhibition but not by dominant-negative RAS,
further supporting a role of MEK in S338 phosphorylation (Fig-ures 5C and 5D). These data showing that CRAFS338 phosphor-
ylation can occur as a consequence of CRAF activation suggest
that it functions as a positive feedback mechanism allowing the
activation of CRAF to convert the CRAF receiver into a CRAF
activator (depicted in Figure 6).
DISCUSSION
The current model of RAF activation is complex and involves
dimerization, phosphorylation, and dephosphorylation as well
as interactions with various accessory proteins and lipids
(Morrison and Cutler, 1997). How these various events areCell 154, 1036–1046, August 29, 2013 ª2013 Elsevier Inc. 1041
Figure 5. CRAF S338 Phosphorylation Is Stimulated by MEK
Activation
(A) MEK inhibitors inhibit CRAF S338 phosphorylation induced by EGF. Un-
transfected 293 cells were pretreated with MEK inhibitor (UO126—20 mM or
PD98059—1 mM), PAK inhibitor (IPA3—20 mM), CAMKII inhibitor (KN-93—
10 mM), or vehicle for 2 hr before addition of EGF (100 ng/ml). Cells were lysed
after 5 min, and CRAF S338 and MEK phosphorylation assessed using
phosphospecific antibodies. See also Figure S2.
(B) Quantification of the effect of kinase inhibitors on CRAF S338 phosphor-
ylation. Results from four separate experiments are presented as mean ±
standard error of the mean (SEM). The amount of S338 phosphorylation from
the EGF treatment alone was set as 1.
(C) Coexpression of constitutively active MEK with CRAF induces S338
phosphorylation. Wild-type HA-CRAF was coexpressed with constitutively
active MEK1 (DD) with and without dominant-negative RAS (RasN17). Cells
were lysedafter 24 hr, and immunoprecipitates preparedwith antibodies toHA.
CRAF S338 phosphorylation was assessed using a phosphospecific antibody.
(D) MEK inhibition blocks CRAF S338 phosphorylation induced by coex-
pression with constitutively active MEK. Cells were prepared as described in
(B), except that MEK (UO126) or ERK inhibitor (ERK inhibitor II) was added
24 hr after transfection. Cells were lysed 2 hr after addition of the inhibitor.
Immunoprecipitates were analyzed as in (B).coordinated to control activation is not known. In the current
model, recruitment of CRAF to the membrane allows the CRAF
NtAmotif to bephosphorylatedbySrc (Fabianet al., 1993;Marais
et al., 1995), PAKs, andPKCs (Kinget al., 1998;Kolchet al., 1993).
For BRAF, these phosphorylations are unnecessary because
446–447 are constitutively phosphorylated and 448–449 are as-
partic acids (Marais et al., 1997; Mason et al., 1999). In a mecha-
nism that was not understood, phosphorylation of the AL occurs
after membrane recruitment, resulting in the activation of RAF.
Here we showed, using a variety of different mutants
(Table S1), that the function of the phosphorylated NtA motif is
to facilitate transactivation, explaining how dimerization func-1042 Cell 154, 1036–1046, August 29, 2013 ª2013 Elsevier Inc.tions to stimulate RAF kinase activity. Our data support a model
wherein the NtA motif engages residues in the partner kinase,
inducing the active conformation. This explains how BRAF inhib-
itor drugs can stimulate MEK and ERK activation and also why
kinase-inactive forms of BRAF can function as oncogenes. The
constitutive phosphorylation of the NtA in BRAF accounts for
its ability to transactivate and is a key functional difference be-
tween BRAF and CRAF. Our work further clarifies another step
in kinase activation by showing that the kinase that phosphory-
lates the AL is RAF itself. Lastly, our findings that NtA phosphor-
ylation is not required for CRAF activation suggested that NtA
phosphorylation could occur after, rather than before, activation.
Consistent with this, we found that MEK inhibition inhibits CRAF
NtA phosphorylation induced by EGF. This introduces a
complexity to the RAF activation pathway by showing that
BRAF and CRAF have distinct functions in the activation of MEK.
A critical part of our approach was based on a previously
generated mutant that is kinase dead but can constitutively
dimerize (Hu et al., 2011). This was important, as differences in
dimerization efficiency might have explained differences be-
tween the ability of BRAF versus CRAF to transactivate. The
use of these constitutively dimeric forms showed clearly that
NtA motif phosphorylation was the major difference.
This difference between BRAF and CRAF suggests that the
stoichiometry between BRAF and CRAF levels could be impor-
tant. CRAF molecules are considered to be more abundant
than BRAF molecules in fibroblasts (Mikula et al., 2001). We
confirmed and quantitated this, showing that CRAF is about 3–
4 times more abundant than BRAF in fibroblast cell lines (Fig-
ure S3). Mathematical modeling illustrated how differences in
stoichiometry between BRAF and CRAF could alter the sensi-
tivity andmagnitude of MEK activation, assuming that NtA phos-
phorylation of CRAF occurred after activation (Figure S4). High
CRAF:BRAF ratios functioned to inhibit signals that are weak
or of short duration. The reduction in signal because CRAF
was initially unable to serve as an activator was minimzed as
signal intensity or the duration of the signal increased. The
CRAF:BRAF ratio is known to vary in tumors (Karreth et al.,
2009), and we find that it can vary significantly between different
cells and tissues (E.A.G., J.H., and A.S.S., unpublished data).
Differences in activation thresholds could play an important
role in determining the quality of MAPK activation.
Differences in expression levels between BRAF and CRAF can
also explain why CRAF is considered an obligate downstream
partner for BRAF. This conclusion is based on results showing
that ERK activation induced by kinase-dead BRAF requires
CRAF but occurs normally in the absence of BRAF (Garnett
et al., 2005; Hatzivassiliou et al., 2010; Poulikakos et al., 2010;
Wan et al., 2004). We confirmed these findings (Garnett et al.,
2005; Wan et al., 2004) but found that overexpressing BRAF in
the CRAF-deficient cell lines could rescue the ability of BRAF in-
hibitors to stimulate ERK (Figure S5). This suggests that the
greater abundance of CRAF expression can explain the direc-
tionality of RAF activation.
Mechanism of RAF Activation
Recently, we proposed amodel wherein the assembly of two hy-
drophobic spines, the catalytic and the regulatory spines, can
Figure 6. Model of RAF Transactivation
(A–F) BRAF (activator) activates CRAF (receiver).
(A) Domains of the RAFmonomer. The two lobes of
the kinase, the Ras-binding domain (RBD), and the
NtA are shown. BRAF is shown here with its
constitutively acidic NtA (pS445/D448) depicted
as a red circle. (B) Recruitment of BRAF to the
plasma membrane (PM) by GTP-RAS induces a
new conformation in the N-terminal half of BRAF.
(C) RAS binding allows two RAF molecules to
dimerize. A BRAF/CRAF dimer is shown here, with
BRAF serving as the ‘‘activator’’ and CRAF as the
‘‘receiver.’’ (D) For BRAF, the NtA is constitutively
phosphorylated (red dot) and lies within the dimer
interface. This allows it to transactivate the RAF
receiver, in this case CRAF. (E) Transactivation
results in cis-autophosphorylation, producing an
active CRAF kinase that can then phosphorylate
MEK. (F) The S338 of the CRAF receiver can be
phosphorylated in a MEK-dependent manner.
CRAF-pS338 is designated as ‘‘CRAF*.’’
(G–J) CRAF* activates CRAF. (G) Monomeric
CRAF* dissociates from BRAF. (H) CRAF* (the
activator) dimerizes with CRAF (the receiver).
CRAF * may also dimerize with, and activate, a
molecule of BRAF. (I) The phosphorylated NtA of
the CRAF* activator lies within the dimer interface
and transactivates the CRAF receiver. (J) Trans-
activation results in cis-autophosphorylation, pro-
ducing an active CRAF kinase that can then
phosphorylate MEK.provide a unifying explanation for protein kinase activation (Kor-
nev et al., 2008; Taylor and Kornev, 2011). We used this model to
test how dimerization, NtA, and AL phosphorylation can work
together to facilitate RAF activation and as a strategy to generate
novel mutants to confirm our hypotheses.
The R-spine is composed of four residues, all from critical sites
in the kinase (Kornev et al., 2006). In BRAF, the top residue is
F516 from the b4 strand of the upper lobe. The second residue
is L505 from the aC helix. The third residue is F595 from the
DFG sequence that defines the N-terminal side of the AL. The
bottom residue is H574 from the conserved HRD motif that
positions catalytic residues and the substrate for phosphate
transfer. In CRAF, the four R-spine residues are F408, L397,
F487, and H466. When all four residues are assembled together
in linear alignment, the kinase is active.Cell 154, 1036–1046,The known function of the conserved
tryptophan in SRC, HCK, CSK, and ITK
suggests that dimerization may function
to position the aC helix and assemble
the R-spine in an active conformation
(Cowan-Jacob et al., 2005; Joseph
et al., 2007; LaFevre-Bernt et al., 1998;
Lin et al., 2005; Xu et al., 1999). When
SRC and HCK are activated, the
conserved tryptophan is displaced from
a hydrophobic pocket between the b4
strand and the aC helix, allowing the aC
helix to swing in (Cowan-Jacob et al.,2005; LaFevre-Bernt et al., 1998). In ITK, the tryptophan is
rotated in the active kinase, allowing the aC helix to move in
(Joseph et al., 2007). L680 of the EGFR plays an analogous
role in EGFR activation (Zhang et al., 2006). Activation of EGFR
forces L680 out of the inhibitory pocket and into the dimer inter-
face, where it plays a second role in stabilizing the dimer. It is
appealing to propose a similar role for the conserved tryptophan
in RAF. In RAF, the tryptophan could be playing multiple, distinct
roles in the inhibited and active conformations as well as in the
dimer interface. When a structure of inactive full-length BRAF
or CRAF is solved, the tryptophan may be positioned in a way
that also contributes to inhibition of the kinase.
In the active kinase, the conserved tryptophan is in the center
of the dimer interface, and the NtA residues that immediately
precede the tryptophan are close by (Figure 3A). No structuresAugust 29, 2013 ª2013 Elsevier Inc. 1043
with CRAF pS338 or BRAF pS446 exist, but the known struc-
tures do show that CRAF Y340 and BRAF D448/D449 lie in the
dimer interface (Hatzivassiliou et al., 2010; Qin et al., 2012;
Wan et al., 2004). Without crystallographic evidence, it is impos-
sible to know exactly how the NtA residues facilitate transactiva-
tion, but the structures show that the AL phosphorylation sites,
the NtA residues, and the aC helix are all situated close to the
dimer interface (Baljuls et al., 2011; Wan et al., 2004) (Figure S6).
AL phosphorylation is usually thought to occur in trans by a
second kinase. In the RAF dimer, AL phosphorylation appears
to occur by cis-autophosphorylation. The conundrum presented
by cis-autophosphorylation is that the kinase must be primed for
cis-autophosphorylation. Although the exact mechanism of cis-
autophosphorylation is unknown, the process of such priming for
RAF must be driven by dimerization. GSK-3b, p38a, and Fus3
are thought to be capable of cis-autophosphorylation, and the
active conformation is induced by protein-binding partners
(Lochhead, 2009), allowing for AL phosphorylation that then sta-
bilizes the active conformation without the binding partner. In the
case of RAF, the activator kinase must be inducing the active
conformation of the receiver. Given the large number of kinases
that are activated by dimerization, it is intriguing to speculate that
the mechanism of cis-autophosphorylation described here
might be a more general phenomenon.
We tested this model by generating a mutant with an R-spine
that was constitutively assembled using the ‘‘spine’’ hypothesis
as a model. Because the first and third residues are both phenyl-
alanines, we predicted that substitution of a phenylalanine for the
second residue, L505 (BRAF), would create a stack of three
phenylalanines, stabilizing the R-spine (Figure 4). As predicted,
the L505F mutant was constitutively active and had a level of
activity similar to the well-known oncogenic V600E mutant.
Like the V600E mutant, the L505F mutant was also active as a
monomer (Freeman et al., 2013). However, the V600E mutation
only works for BRAF, whereas the R-spine mutation activates
both BRAF and CRAF, supporting the broad applicability of the
spine hypothesis in dissecting kinase activation. AL phosphory-
lation also occurred when the mutated CRAF was expressed in
bacteria, supporting the idea that AL phosphorylation occurs
by cis-autophosphorylation. The fact that mutation of a single
hydrophobic residue is sufficient to short-circuit the entire regu-
latory pathway involving RAS, dimerization, multiple phosphory-
lations, and multiple binding partners illustrates the power of this
mutation.
Distinct Roles for CRAF, BRAF, and KSR1 in ERK
Activation
A role for activators and receivers in RAF activation could have
important implications for understanding RAF activation. When
RAS is initially activated, BRAF functions mainly as an activator.
If CRAF phosphorylation on 338–341 were to occur coincident
with membrane recruitment and before dimerization, CRAF
and BRAF would both function as activators and receivers. But
if CRAF phosphorylation occurs after activation, dimers formed
early in the signaling response would be asymmetrical with one
activator and one receiver kinase. Over time, as CRAFmolecules
become phosphorylated, they could then function as activator
molecules, able to activate either BRAF or CRAF. This model1044 Cell 154, 1036–1046, August 29, 2013 ª2013 Elsevier Inc.(Figure 6) is supported by our experiments showing that MEK
controls NtA phosphorylation of CRAF and a recent report that
MEK can activate CRAF (Leicht et al., 2013). Whether MEK can
directly phosphorylate the NtA, or whether this is the property
of an intermediary kinase, is not known.
Our data also have implications regarding the role of KSR1 in
RAF activation. In its unphosphorylated state, KSR dimerization
with BRAF or CRAF did not stimulate any detectable RAF kinase
activity (Brennan et al., 2011; Hu et al., 2011). Interestingly, Bar-
ford and coworkers showed that BRAF dimerization with KSR2
could stimulate KSR2 kinase activity toward MEK (Brennan
et al., 2011). It will be interesting to determine whether the
BRAF NtA mediates this effect. By constitutively dimerizing
with BRAF, unphosphorylated KSR1 could function as a buffer
to block BRAF activation (McKay et al., 2011). This could be
important in the resting cell, when BRAF is capable of forming
functional dimers, preventing BRAF from activating itself.
When KSR1 is phosphorylated, it is capable of functioning as
an activator. Without better reagents, we were unable to prove
that KSR1 is phosphorylated at any of the tyrosine, serine, or
threonine sites that we tested. But the data suggest that KSR1
phosphorylation could serve as a convergence point for up-
stream kinases to activate MEK and ERK in a RAS-independent
way. These studies reveal ways to think about RAF isoforms and
how their differences could be used to modulate signaling
through the MAPK signaling pathway.
EXPERIMENTAL PROCEDURES
Biochemicals
PLX4720 (Selleck Chemicals), UO126 (Sigma), and ERK inhibitor II (Millipore)
were purchased. Antibodies: anti-pERK1/2, anti-pMEK1/2, anti-pSer338
CRAF, and anti-MEK1/2 were purchased from Cell Signaling Technology;
anti-pThr598 BRAF were from Thermal Scientific; anti-BRAF and anti-ERK2
were from Santa Cruz Biotechnology; and HRP-labeled secondary antibodies
were from Jackson Laboratories.
Plasmids and Cell Lines
All mutations were generated by PCR and tagged with either HA, Myc, or
FLAG. pCDNA3.1 (Invitrogen) was used for transient expression and viral vec-
tors for stable expression.
The KSR1/ mouse embryonic fibroblasts (MEFs) were described previ-
ously (Nguyen et al., 2002). The CRAF/ MEFs were purchased (Hu¨ser
et al., 2001). The BRAF/ MEFs were generated in the lab.
Cell Culture, Transfection, and Transduction
All cell lines were maintained in DMEM medium with 10% FBS. Cells were
transfected using Lipofectamine 2000 (Invitrogen), harvested at 48 hr, and
lysed in RIPA buffer supplemented with protease and phosphatase inhibitors.
Stable cell lines were generated by retro- or lentiviruses generated using
293T cells transfected with appropriate viral packaging vectors. Viral superna-
tants were collected at 48 and 72 hr and used to infect target cells, following
standard protocols (Hu et al., 2008). Transduced cells were selected by either
cell sorting or antibiotics.
Immunoprecipitation, In Vitro Kinase Assay, and Western Blotting
Immunoprecipitations were performed as described before (Hu et al., 2011).
Briefly, whole-cell lysates were mixed with either anti-HA (Sigma), anti-FLAG
(Sigma), or anti-Myc (Millipore) beads, rotated at 4C for 60 min, and washed
with RIPA buffer. For in vitro kinase assays, the immunoprecipitates were
washed with kinase reaction buffer (25 mM HEPES, 10 mM MgCl2, 0.5 mM
Na3VO4, 0.5 mM DTT, pH 7.4), then incubated with kinase reaction buffer
plus 2 mg inactive MEK1 and 100 mM ATP per sample at room temperature for
30 min. Kinase reaction was stopped by adding 5 ml 43 Laemmli sample
buffer. Immunoblotting was carried out as described before (Hu et al., 2011).SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and one table and can be found
with this article online at http://dx.doi.org/10.1016/j.cell.2013.07.046.
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